Holen Sie sich die Stockscreener-App
61.31
2.06%
1.24
Handel nachbörslich:
61.30
-0.01
-0.02%
Schlusskurs vom Vortag:
$60.07
Offen:
$60.5
24-Stunden-Volumen:
2.21M
Relative Volume:
0.79
Marktkapitalisierung:
$11.78B
Einnahmen:
$2.95B
Nettoeinkommen (Verlust:
$523.88M
KGV:
22.79
EPS:
2.69
Netto-Cashflow:
$620.18M
1W Leistung:
+3.16%
1M Leistung:
+14.81%
6M Leistung:
+6.79%
1J Leistung:
-9.71%
1-Tages-Spanne:
$60.34
$61.88
1-Wochen-Bereich:
$58.38
$61.88
52-Wochen-Spanne:
$50.76
$73.51
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Firmenname
Biomarin Pharmaceutical Inc
Sektor
Branche
Telefon
(415) 506-6700
Adresse
105 DIGITAL DRIVE, NOVATO, CA
Vergleichen Sie BMRN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
61.31 | 11.54B | 2.95B | 523.88M | 620.18M | 2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-03 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-11-06 | Herabstufung | Stifel | Buy → Hold |
| 2025-09-08 | Eingeleitet | H.C. Wainwright | Neutral |
| 2025-09-03 | Eingeleitet | Raymond James | Outperform |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-02-24 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-30 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-08-20 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | Eingeleitet | Evercore ISI | Outperform |
| 2023-11-15 | Eingeleitet | Wells Fargo | Overweight |
| 2023-10-23 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | Eingeleitet | Raymond James | Mkt Perform |
| 2023-09-18 | Eingeleitet | UBS | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Perform |
| 2023-07-05 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-03-21 | Eingeleitet | Bernstein | Underperform |
| 2023-02-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-02-21 | Eingeleitet | Citigroup | Neutral |
| 2023-01-30 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Hold |
| 2022-10-31 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-13 | Fortgesetzt | Wedbush | Neutral |
| 2022-04-25 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | Fortgesetzt | Jefferies | Buy |
| 2021-09-09 | Hochstufung | Stifel | Hold → Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-04 | Fortgesetzt | Guggenheim | Buy |
| 2021-03-01 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-08-20 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-08-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2020-08-19 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | Herabstufung | Stifel | Buy → Hold |
| 2020-07-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | Bestätigt | Citigroup | Buy |
| 2020-01-28 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-01-27 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-01-24 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-05-23 | Fortgesetzt | Citigroup | Buy |
| 2019-04-09 | Fortgesetzt | Raymond James | Outperform |
| 2019-01-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | Eingeleitet | Wolfe Research | Outperform |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-08-07 | Bestätigt | Stifel | Buy |
| 2018-08-03 | Bestätigt | Stifel | Buy |
Alle ansehen
Biomarin Pharmaceutical Inc Aktie (BMRN) Neueste Nachrichten
HC Wainwright: BioMarin’s (BMRN) Amicus acquisition stabilizes cash flow while Voxzogo remains near-term driver - MSN
10 Magnificent Stocks That Can Make You Richer in 2026 - The Motley Fool
How Investors Are Reacting To BioMarin (BMRN) Halting BMN349 And Refocusing Its Rare Disease Pipeline - Yahoo Finance
19,329 Shares in BioMarin Pharmaceutical Inc. $BMRN Acquired by Financiere des Professionnels Fonds d investissement inc. - MarketBeat
Technical Analysis: What RSI levels show for BioMarin Pharmaceutical Inc BM8 stock2025 Market Trends & Free Expert Verified Stock Movement Alerts - moha.gov.vn
Investor Mood: How BioMarin Pharmaceutical Inc stock performs in weak economyJuly 2025 Pullbacks & Safe Entry Trade Reports - moha.gov.vn
Blue Trust Inc. Sells 17,973 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin’s $4.8 Billion Amicus Acquisition: A Strategic Pivot to Rare Disease Dominance - FinancialContent
These nine Bay Area drug makers are hurtling toward key FDA approval decisions in 2026 - The Business Journals
VIRGINIA RETIREMENT SYSTEMS ET Al Reduces Stock Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
H.C. Wainwright: BioMarin’s (BMRN) Amicus Acquisition Stabilizes Cash Flow While Voxzogo Remains Near-Term Driver - Insider Monkey
H.C. Wainwright: BioMarin's (BMRN) Amicus Acquisition Stabilizes Cash Flow While Voxzogo Remains Near-Term Driver - Finviz
12 Best NASDAQ Stocks to Buy in 2026 - Insider Monkey
BioMarin Acquiring Amicus — Both Great Companies, Only One Worth Buying Now (NASDAQ:BMRN) - Seeking Alpha
Is BioMarin Pharmaceutical Inc. (BMRN) the Ridiculously Cheap Stock to Buy Now? - Finviz
Cwm LLC Has $8.90 Million Stock Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
BioCentury’s 2025-26 picks and predictions. Plus: BioMarin and more biotech ICYMI — a BioCentury podcast - BioCentury
Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal - FinancialContent
BioMarin ends development of BMN 349 AATD therapy - MSN
BioMarin to Acquire Amicus Therapeutics for $4.8B - Contract Pharma
Rocket Lab, Micron, And CoreWeave Are Among the Top 10 Large-Cap Gainers Last Week (Dec. 22-Dec. 26): Are the Others in Your Portfolio?Astera Labs (NASDAQ:ALAB), BioMarin Pharmaceutical (NASDAQ:BMRN), Ciena (NYSE:CIEN), CoreWeave (NA - Benzinga
Portfolio Update: How BioMarin Pharmaceutical Inc stock performs in weak economy2025 Earnings Impact & Long-Term Investment Growth Plans - moha.gov.vn
Rice Hall James & Associates LLC Boosts Stock Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin Pharmaceutical Inc. $BMRN Shares Acquired by Pacer Advisors Inc. - MarketBeat
BioMarin Pharmaceuticals: Amicus Transforms Business Case Overnight (NASDAQ:BMRN) - Seeking Alpha
Weekly Buzz: FDA OKs Roche's Lunsumio VELO; It's No For Tolbrutinib; BioMarin, SNY Open Wallets - RTTNews
Swedbank AB Buys 35,000 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin names new chief accounting officer - MSN
Silver Tops $70, Novo Nordisk Soars 9% On Obesity Pill ApprovalBullish (NYSE:BLSH), BioMarin Pharmaceutical (NASDAQ:BMRN) - Benzinga
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion - New Jersey Business Magazine
BioMarin Pharmaceutical (BMRN) Stock Is Up, What You Need To Know - Finviz
What's Going On With BioMarin Stock On Tuesday? - Sahm
BioMarin Pharmaceutical (NASDAQ:BMRN) Trading 3.9% Higher on Analyst Upgrade - MarketBeat
BioMarin Pharmaceutical (NASDAQ:BMRN) Given New $100.00 Price Target at Truist Financial - MarketBeat
Analysts Grow More Bullish on BioMarin Pharmaceuticals Inc. (BMRN) After Amicus Acquisition - Finviz
Analysts grow more bullish on BioMarin Pharmaceuticals Inc. (BMRN) after Amicus acquisition - MSN
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Lexicon Pharmaceuticals (LXRX) and Pfizer (PFE) - The Globe and Mail
Narrow-Moat BioMarin's $4.8 Billion Deal for Amicus Therapeutics Expands Rare Disease Portfolio - Morningstar
Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (ABBV), Disc Medicine (IRON) and BioMarin Pharmaceutical (BMRN) - The Globe and Mail
BioMarin (BMRN) Stock News Today: Amicus Acquisition Fallout, BMN 349 Cut, and Fresh Wall Street Price Targets (Dec. 22, 2025) - ts2.tech
American biotech company BioMarin acquires Amicus Therapeutics for $4.8 billion - AKM.RU
BioMarin: Amicus Buyout Sparks My Enthusiasm (NASDAQ:BMRN) - Seeking Alpha
BioMarin to Buy Rare Disease Drugmaker Amicus Therapeutics for $4.8B - sharewise.com
7 Most Promising Gene Editing Stocks According to Analysts - Insider Monkey
BioMarin snaps up Amicus Therapeutics for $4.8bn amid rare disease push - Pharmaceutical Technology
BioMarin quietly discards liver disease candidate after $4.8B Amicus announcement - Fierce Biotech
BioMarin stock price target raised to $100 from $80 at Truist Securities - Investing.com UK
BioMarin stock price target raised to $100 from $80 at Truist Securities By Investing.com - Investing.com Australia
BioMarin drops development of liver, lung disease asset - Seeking Alpha
Truist Securities Lifts BioMarin Pharmaceutical Price Target to $100 From $80, Maintains Buy Rating - marketscreener.com
Finanzdaten der Biomarin Pharmaceutical Inc-Aktie (BMRN)
Umsatz
Nettogewinn
Free Cashflow
ENV
28.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):